Qureight

Qureight is a Cambridge-based health technology company founded in 2018 that is transforming how clinical trial data is curated and analysed for drug development. The company was born from a shared realisation by its physician co-founders that complex imaging and biomarker data from patients with lung and heart diseases was being collected but not effectively used — slowing the development of treatments for conditions such as idiopathic pulmonary fibrosis, lung cancer and pulmonary hypertension.

Qureight's cloud-based platform uses AI and machine learning to structure CT scan images, biomarker data and clinical trial records, turning raw datasets into actionable endpoints that pharmaceutical companies can use to design better trials and evaluate drug efficacy faster. A key capability is the company's Synthetic Control Arms technology, which digitally twins clinical study cohorts to reduce the need for placebo arms, accelerating trial timelines and cutting costs. Biopharma clients including Roche, Galapagos and Takeda use the platform commercially.

Qureight has raised over $11 million across three funding rounds, including a $6.8 million Series A in 2024, backed by investors including Playfair Capital, Cambridge Angels, Ascension and Meltwind. The company has expanded internationally with partnerships including King Faisal Specialist Hospital in Saudi Arabia and Oslo-based Calluna Pharma, and recently moved into its own WeWork offices on Station Road in Cambridge as it scales its team of clinicians, machine learning engineers and data scientists.